This study represents (to the best of our knowledge) the first clinical validation of a molecular imaging biomarker for malignancy. (124)I-girentuximab PET/CT can accurately and noninvasively identify ccRCC, with potential utility for designing best management approaches for patients with renal masses.
No takes yet. Share an insight, caveat, or question.
Divgi et al. (2012) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: